Home  /  Resource Library  /  Frontline Axi-Cel Achieves High Response Rate in High-Risk LBCL

Frontline Axi-Cel Achieves High Response Rate in High-Risk LBCL

Transplantation and Cellular Therapy 2022: Results of a study examining CAR T threapy axicabtagene ciloleucel as first line treatment for aggressive large cell lymphomas.